Florbetapir positron emission tomography and cerebrospinal fluid biomarkers

Alzheimer's Disease Neuroimaging Initiative

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Abstract Background We evaluated the relationship between florbetapir-F18 positron emission tomography (FBP PET) and cerebrospinal fluid (CSF) biomarkers. Methods Alzheimer's Disease Neuroimaging Initiative-Grand Opportunity and Alzheimer's Disease Neuroimaging Initiative 2 (GO/2) healthy control (HC), mild cognitive impairment (MCI), and Alzheimer's disease (AD) dementia subjects with clinical measures and CSF collected ±90 days of FBP PET data were analyzed using correlation and logistic regression. Results In HC and MCI subjects, FBP PET anterior and posterior cingulate and composite standard uptake value ratios correlated with CSF amyloid beta (Aβ1-42) and tau/Aβ1-42 ratios. Using logistic regression, Aβ1-42, total tau (t-tau), phosphorylated tau181P (p-tau), and FBP PET composite each differentiated HC versus AD. Aβ1-42 and t-tau distinguished MCI versus AD, without additional contribution by FBP PET. Total tau and p-tau added discriminative power to FBP PET when classifying HC versus AD. Conclusion Based on cross-sectional diagnostic groups, both amyloid and tau measures distinguish healthy from demented subjects. Longitudinal analyses are needed.

Original languageEnglish (US)
Article number1970
Pages (from-to)986-993
Number of pages8
JournalAlzheimer's and Dementia
Volume11
Issue number8
DOIs
StatePublished - Aug 1 2015

    Fingerprint

Keywords

  • Alzheimer's Disease Neuroimaging Initiative
  • Alzheimer's disease
  • Biomarkers
  • Cerebrospinal fluid
  • Florbetapir positron emission tomography
  • Mild cognitive impairment

ASJC Scopus subject areas

  • Epidemiology
  • Health Policy
  • Developmental Neuroscience
  • Clinical Neurology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience

Cite this